Read our statement to Gilead Sciences urging faster access to Lenacapavir for vulnerable populations, particularly adolescent girls and young women.

The THRIVE consortium (Transforming Advanced HIV Disease CaRe in LMICs through Comprehensive and Equitable Access) – comprised of CHAI, Afrocab, Penta and operational research partners Zvitambo and Mildmay Uganda – was formed to dramatically reduce mortality among adults and CLHIV by enabling global access to critical prevention, screening, and treatment commodities, and centring local leadership […]

The THRIVE consortium (Transforming Advanced HIV Disease CaRe in LMICs through Comprehensive and Equitable Access) – comprised of CHAI, Afrocab, Penta and operational research partners Zvitambo and Mildmay Uganda – was formed to dramatically reduce mortality among adults and CLHIV by enabling global access to critical prevention, screening, and treatment commodities, and centring local leadership […]

The THRIVE consortium (Transforming Advanced HIV Disease CaRe in LMICs through Comprehensive and Equitable Access) – comprised of CHAI, Afrocab, Penta and operational research partners Zvitambo and Mildmay Uganda – was formed to dramatically reduce mortality among adults and CLHIV by enabling global access to critical prevention, screening, and treatment commodities, and centring local leadership […]

Afrocab Treatment Access Partnership (Afrocab) is seeking a consultant to conduct a benchmarking exercise to provide a recommendation for the salary, benefits and remuneration structure aligned to current market pay for a multi-country regional network organization. For requirements, how to apply and detailed consultancy descriptions, click on the link below:

Afrocab has openings for a Technical Director, Finance and Administration Manager and Administrative Associate. For requirements, how to apply and detailed job descriptions, click on the links below:

In a small single-arm, open-label trial in Portugal, dolutegravir + two NRTIs proved effective and safe for managing HIV-2 infection. Data are sparse regarding treatment of HIV-2 infection with contemporary ART regimens; moreover, HIV-2 exhibits intrinsic resistance to NNRTIs. Further complicating the management of HIV-2 infection is the fact that plasma HIV-2 RNA levels, when […]

We are sharing a statement from a community and civil society leaders, advocates and activists meeting on long-acting drugs for the prevention and treatment of HIV which took place in Nairobi in April 2023.In this statement, the community demands rapid action from Gilead to make Lenacapavir accessible in low and middle-income countries without further delay! […]

Greetings from Afrocab, SMART4TB is a US$200 million investment from USAID to tackle tuberculosis (TB) through research and its translation to policy and practice. The SMART4TB project is led by Johns Hopkins University and an international consortium of research partners and civil society organizations. SMART4TB will run through 2027 and will support research across five […]

In April 2023, the CAB hosted a meeting on long-acting technologies and introduction pathways. Presentations, discussions, and panel sessions featured CAB members, Ministry of Health officials, and supplier and industry representatives across two days. The sessions covered key focal areas across the product introduction pathway to inform a third and final day of work-planning and advocacy […]